Lurbinectedin (PM01183)/Doxorubicin
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Lurbinectedin (PM01183)/Doxorubicin, covering 2021-10-28 to 2021-10-28. Get the full timeline:
Most recent: Clinical Trial Update: Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer [Phase 3]